Technical Analysis for INNT - Innovate Biopharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 1.96 -5.31% -0.11
INNT closed down 1.9 percent on Thursday, March 21, 2019, on 1.13 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical INNT trend table...

Date Alert Name Type % Chg
Mar 21 20 DMA Support Bullish -5.31%
Mar 21 New Uptrend Bullish -5.31%
Mar 21 Calm After Storm Range Contraction -5.31%
Mar 21 Narrow Range Bar Range Contraction -5.31%
Mar 21 NR7 Range Contraction -5.31%
Mar 21 Down 3 Days in a Row Weakness -5.31%
Mar 21 Oversold Stochastic Weakness -5.31%
Mar 20 Fell Below 50 DMA Bearish -7.11%
Mar 20 20 DMA Support Bullish -7.11%
Mar 20 Calm After Storm Range Contraction -7.11%

Older signals for INNT ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Innovate Biopharmaceuticals, Inc., formerly Monster Digital, Inc., is a clinical stage biotechnology company. The Company is focused on developing novel autoimmune and inflammation therapeutic drugs. Its lead drug candidate, larazotide acetate (INN-202) is a tight junction regulator. Its other products include INN-108 and INN-329 (Secretin). The Company’s INN-108 is a novel small molecule comprised of two active parts with anti- inflammatory and immunodulatory properties coupled through an azo bond. The Company is developing INN-108 as a therapeutic for Ulcerative Colitis (UC). Its Secretin stimulated magnetic resonance cholangiopancreatography (MRCP) is a ionizing, radiation-free assessment of the pancreaticobiliary system. The Company has completed a phase II b clinical trial for celiac disease for INN-202. It is developing INN-108 in a phase II trial for inflammatory bowel disorders, mild to moderate UC and a Gastrointestinal (GI) orphan disease.
Medicine Biotechnology Biopharmaceutical Medical Specialties Autoimmune Diseases Radiation Inflammation Inflammatory Bowel Disease Ulcerative Colitis Abdominal Pain Diarrhea Colitis Digestive Diseases Gastrointestinal Tract Celiac Disease
Is INNT a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 3 bearish and 0 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 50.5
52 Week Low 1.7
Average Volume 377,969
200-Day Moving Average 5.7803
50-Day Moving Average 2.1686
20-Day Moving Average 2.049
10-Day Moving Average 2.151
Average True Range 0.2936
ADX 26.88
+DI 51.3199
-DI 12.0192
Chandelier Exit (Long, 3 ATRs ) 3.4392
Chandelier Exit (Short, 3 ATRs ) 2.5808
Upper Bollinger Band 2.3497
Lower Bollinger Band 1.7483
Percent B (%b) 0.53
BandWidth 29.350903
MACD Line 0.003
MACD Signal Line -0.0189
MACD Histogram 0.0219
Fundamentals Value
Market Cap 19.35 Million
Num Shares 9.35 Million
EPS -0.89
Price-to-Earnings (P/E) Ratio -2.32
Price-to-Sales 1.94
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.24
Resistance 3 (R3) 2.24 2.18 2.21
Resistance 2 (R2) 2.18 2.14 2.18 2.20
Resistance 1 (R1) 2.13 2.12 2.10 2.13 2.19
Pivot Point 2.07 2.07 2.06 2.07 2.07
Support 1 (S1) 2.02 2.03 1.99 2.02 1.95
Support 2 (S2) 1.96 2.01 1.96 1.94
Support 3 (S3) 1.91 1.96 1.93
Support 4 (S4) 1.91